Pfizer Presented Phase 3 Litfulo Trial Results
Pfizer revealed new clinical data demonstrating that Litfulo treatment improved repigmentation in patients with nonsegmental vitiligo.
Updated on Oct. 13, 2026 in Biotech
Live Poll
Would you personally favor using new oral medications to treat chronic autoimmune skin conditions?
Pfizer presented phase 3 trial results for its once-daily oral treatment Litfulo at the 35th European Academy of Dermatology and Venereology Annual Congress. The data showed that Litfulo dosages significantly improved facial and total body repigmentation compared to a placebo.
Why it matters
The study suggests that targeting immune cell signaling can stabilize vitiligo and repair the skin by preventing the destruction of melanin-producing cells. This development offers a potential new systemic therapy for patients managing the condition's severity.
The phase 3 program evaluated 100mg and 50mg once-daily oral dosages of Litfulo. Participants demonstrated reduced disease severity compared to those in the placebo group.
The players
Pfizer
Pfizer is a global pharmaceutical corporation that develops and manufactures a wide range of medications and vaccines.
European Academy of Dermatology and Venereology
The European Academy of Dermatology and Venereology is a non-profit organization focused on advancing clinical practice and research in skin and venereal diseases.
The details
The TRANQUILLO and TRANQUILLO 2 trials tested the drug's efficacy in addressing the immune cell signaling pathways responsible for depleting melanin. Litfulo utilizes dual selectivity for JAK3 and the TEC family kinases to stabilize the disease.
Timeline
October 13, 2026: Results were presented at the 35th European Academy of Dermatology and Venereology Annual Congress.
The Big Picture
The presentation of these results at the European Academy of Dermatology and Venereology Annual Congress highlights the ongoing focus on systemic JAK-inhibitor treatments in dermatology. These findings mark a major milestone in the evaluation of JAK-targeted therapies for autoimmune skin conditions.
Patients may eventually see Litfulo as a new, once-daily oral option for managing nonsegmental vitiligo symptoms. The potential for improved repigmentation and disease stabilization represents a shift in current treatment accessibility for those with the condition.
The takeaway
This trial data underscores the growing precision of kinase-inhibiting drugs in treating autoimmune skin disorders. Patients should consult with dermatologists regarding the evolving landscape of systemic vitiligo therapies as regulatory reviews progress.
Further reading
For more on the latest developments in medical innovation, visit the Biotech section.
Live Poll
Would you personally favor using new oral medications to treat chronic autoimmune skin conditions?
